Tags : Orexo

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria Published: Aug 23, 2019 | Tags: OxThera, Oxabact, Receives, EMA, Positive Decision, Pediatric Investigational Plan, Treat, Primary Hyperoxaluria 2.Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program Published: Aug 22, 2019 | Tags: Novartis, Signs, Option Agreement, Iconic Therapeutics, Ophthalmology […]Read More

Orexo Enters into an Agreement with GAIA to Develop and

Shots: GAIA to receive royalties, milestone and financial compensation during the development phase. Orexo to get exclusive WW rights to commercialize DTx (OXD-01) and is responsible for the clinical development, regulatory approval and commercialization activities The DTx is based on GAIA’s Broca technology platform which is an AI-expert system that engaged users in personalized and […]Read More